Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
life sciences
national
national blog main
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
eli lilly
fda
indiana blog main
indiana top stories
abbvie
alzheimer's disease
boehringer ingelheim
cancer
clinical trials
crispr
democrats
europe blog main
europe top stories
gene editing
glaxosmithkline
What
bio
moves
4
×
roundup
week
4
×
ceo
debut
acquisitions
america
big
biggest
biogen
black
bosley's
bosley’s
bridge
bucks
build
buy
cas
companies
company’s
continue
continues
convoluted
crime
crispr
daniel
democrats
departure
diamond
diamond’s
dreams
drug
dyne’s
editas
exit
gilead
guiding
head
headaches
Language
unset
Current search:
moves
×
week
×
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
4 years ago
Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More
@xconomy.com
4 years ago
Bio Roundup: Head and Spine Previews, Biogen Moves, IPO Dreams & More
@xconomy.com
5 years ago
Bio Roundup: Bosley’s Editas Exit, Bridge Bucks, CRISPR Crime & More
